Tissue-specific consequences of cyclin D1 overexpression in prostate cancer progression
- PMID: 17804732
- DOI: 10.1158/0008-5472.CAN-07-0418
Tissue-specific consequences of cyclin D1 overexpression in prostate cancer progression
Abstract
The cyclin D1 oncogene encodes the regulatory subunit of a holoenzyme that phosphorylates and inactivates the Rb protein and promotes progression through G(1) to S phase of the cell cycle. Several prostate cancer cell lines and a subset of primary prostate cancer samples have increased cyclin D1 protein expression. However, the relationship between cyclin D1 expression and prostate tumor progression has yet to be clearly characterized. This study examined the effects of manipulating cyclin D1 expression in either human prostatic epithelial or stromal cells using a tissue recombination model. The data showed that overexpression of cyclin D1 in the initiated BPH-1 cell line increased cell proliferation rate but did not elicit tumorigenicity in vivo. However, overexpression of cyclin D1 in normal prostate fibroblasts (NPF) that were subsequently recombined with BPH-1 did induce malignant transformation of the epithelial cells. The present study also showed that recombination of BPH-1 + cyclin D1-overexpressing fibroblasts (NPF(cyclin D1)) resulted in permanent malignant transformation of epithelial cells (BPH-1(NPF-cyclin D1) cells) similar to that seen with carcinoma-associated fibroblasts (CAF). Microarray analysis showed that the expression profiles between CAFs and NPF(cyclin D1) cells were highly concordant including cyclin D1 up-regulation. These data indicated that the tumor-promoting activity of cyclin D1 may be tissue specific.
Similar articles
-
ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo.Cancer Res. 2007 May 1;67(9):4364-72. doi: 10.1158/0008-5472.CAN-06-1898. Cancer Res. 2007. PMID: 17483350
-
Prolonged response to antisense cyclin D1 in a human squamous cancer xenograft model.Clin Cancer Res. 2000 Feb;6(2):654-60. Clin Cancer Res. 2000. PMID: 10690551
-
Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1.Oncogene. 1998 Apr 16;16(15):1913-20. doi: 10.1038/sj.onc.1201719. Oncogene. 1998. PMID: 9591774
-
Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation.Lung Cancer. 2007 Jan;55(1):1-14. doi: 10.1016/j.lungcan.2006.09.024. Epub 2006 Oct 27. Lung Cancer. 2007. PMID: 17070615 Review.
-
Minireview: Cyclin D1: normal and abnormal functions.Endocrinology. 2004 Dec;145(12):5439-47. doi: 10.1210/en.2004-0959. Epub 2004 Aug 26. Endocrinology. 2004. PMID: 15331580 Review.
Cited by
-
A mathematical model of cancer stem cell driven tumor initiation: implications of niche size and loss of homeostatic regulatory mechanisms.PLoS One. 2013 Aug 19;8(8):e71128. doi: 10.1371/journal.pone.0071128. eCollection 2013. PLoS One. 2013. PMID: 23990931 Free PMC article.
-
Role of cyclin D1 immunoreactivity and AgNOR staining in the evaluation of benign and malignant lesions of the prostate.Prostate Int. 2014;2(2):90-6. doi: 10.12954/PI.14041. Epub 2014 Jun 30. Prostate Int. 2014. PMID: 25032195 Free PMC article.
-
Modeling stromal-epithelial interactions in disease progression.Discov Med. 2010 Jun;9(49):504-11. Discov Med. 2010. PMID: 20587339 Free PMC article.
-
Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer.Oncotarget. 2017 Nov 30;8(67):111225-111245. doi: 10.18632/oncotarget.22760. eCollection 2017 Dec 19. Oncotarget. 2017. PMID: 29340049 Free PMC article.
-
Interaction of prostate carcinoma-associated fibroblasts with human epithelial cell lines in vivo.Differentiation. 2017 Jul-Aug;96:40-48. doi: 10.1016/j.diff.2017.07.002. Epub 2017 Jul 20. Differentiation. 2017. PMID: 28779656 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials